AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

10,678.00p
   
  • Change Today:
    -64.00p
  • 52 Week High: 12,294.00
  • 52 Week Low: 9,501.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.21m
  • Volume: 1,276,799
  • Market Cap: £165,531m
  • RiskGrade: 123

Thursday broker round-up

By Caoimhe Toman

Date: Thursday 20 Feb 2020

LONDON (ShareCast) - (Sharecast News) - Travis Perkins: Citigroup upgrades to buy with a target price of 1,900p.

Hochschild Mining: Berenberg reiterates hold with a target price of 190p.

Morgan Sindall: Liberum reiterates hold with a target price of 1,850p.

Spectris: Liberum reiterates hold with a target price of 2,400p.

Rathbone Brothers: Liberum reiterates hold with a target price of 2,100p.

Mondi: Deutsche Bank reiterates buy with a target price of 1,950p.

Meggitt: Credit Suisse reiterates underperform with a target price of 520p.

AstraZeneca: Barclays reiterates overweight with a target price of 8,500p.

GlaxoSmithKline: Barclays reiterates underweight with a target price of 1,550p.

Hikma Pharmaceuticals: Barclays reiterates equal weight with a target price of 1,900p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 10,678.00p
Change Today -64.00p
% Change -0.60 %
52 Week High 12,294.00
52 Week Low 9,501.00
Volume 1,276,799
Shares Issued 1,550.21m
Market Cap £165,531m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average88.49% below the market average
92.59% below the sector average92.59% below the sector average92.59% below the sector average92.59% below the sector average92.59% below the sector average
Price Trend
10.86% above the market average10.86% above the market average10.86% above the market average10.86% above the market average10.86% above the market average
61.40% above the sector average61.40% above the sector average61.40% above the sector average61.40% above the sector average61.40% above the sector average
Income
85.37% below the market average85.37% below the market average85.37% below the market average85.37% below the market average85.37% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
81.43% above the market average81.43% above the market average81.43% above the market average81.43% above the market average81.43% above the market average
94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average94.59% above the sector average

What The Brokers Say

Strong Buy 7
Buy 13
Neutral 6
Sell 0
Strong Sell 2
Total 28
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 28-Mar-2024

Time Volume / Share Price
16:58 10,298 @ 10,757.95p
16:39 600 @ 10,678.00p
16:37 1,835 @ 10,678.00p
16:35 600 @ 10,678.00p
16:35 400 @ 10,678.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page